Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002535 · ClinicalTrials.gov registry record · Phase 2
Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma
A Phase 2 study of Melanoma (Skin), sponsored by St. Luke's Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Study location
NCT00002535: Completed Phase 2 study of Melanoma (Skin), sponsored by St. Luke's Medical Center.
NCT00002535 is a Phase 2 study of Melanoma (Skin) that has completed, run by St. Luke's Medical Center. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002535, a Phase 2 study of Melanoma (Skin), has completed, sponsored by St. Luke's Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop tumor cells from growing. Combining biological therapies with indomethacin and cyclophosphamide may kill more tumor cells. PURPOSE: Phase II trial to compare the effectiveness of indomethacin and biological therapy with or without cyclophosphamide in treating patients who have advanced melanoma that has not responded to previous therapy.
Conditions Studied
Interventions
- DRUG cyclophosphamide
- BIOLOGICAL aldesleukin
- BIOLOGICAL therapeutic tumor infiltrating lymphocytes
- BIOLOGICAL lymphokine-activated killer cells
- DRUG indomethacin
Study Locations (1)
Wisconsin
- St. Luke's Medical Center - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Start Date | 1993-07 |
| Est. Completion | 2004-07 |
| Phase | Phase 2 |
What the finished NCT00002535 record still lists
NCT00002535 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Melanoma (Skin) appearing as the primary indexed condition, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00002535 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT00002535 about?
NCT00002535 is a clinical study titled "Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma". RATIONALE: Biological therapies use different ways to stimulate the immune system and stop tumor cells from growing. Combining biological therapies with indomethacin and cyclophosphamide may kill more tumor cells. PURPOSE: Phase II trial to compare the effectiveness of indomethacin and biological t...
What is the current status of trial NCT00002535?
This trial is currently completed. It is a Phase 2 study. The study started on 1993-07. Estimated completion is 2004-07.
What conditions does trial NCT00002535 study?
This clinical trial studies the following conditions: Melanoma (Skin).
What interventions are being tested in trial NCT00002535?
The interventions under investigation include: cyclophosphamide (DRUG), aldesleukin (BIOLOGICAL), therapeutic tumor infiltrating lymphocytes (BIOLOGICAL), lymphokine-activated killer cells (BIOLOGICAL), indomethacin (DRUG).
Who is sponsoring clinical trial NCT00002535?
This trial is sponsored by St. Luke's Medical Center, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002535 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma (Skin)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
RECRUITING · Phase 2
-
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
RECRUITING · Phase 2
-
Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma
COMPLETED · Phase 2
-
Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery
COMPLETED · Phase 2
-
Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma
COMPLETED · Phase 2
-
Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia